The Board of Directors at A+ Science has appointed Håkan Fröderberg as the new CEO.
Håkan Fröderberg has extensive experience from leading positions in several companies within the life science industry. The board is confident that Håkan with his background and experience is the right person to lead and contribute in developing the company, its people, services and business relationships, it states.
Fröderberg started at A+ Science on August 17, 2020. He replaces Martin Tiberg who has been an interim CEO since April 2, 2020 when Jennifer Heyno left the company.
An experienced leader
Before joining A+ Science, Håkan Fröderberg worked at Celgene as a Business Unit Director and was a member of the Nordic management team. Prior to that, he was the Nordic CEO of Nigaard Pharma AS / Zambon, where he built the current organization. During his career in the pharmaceutical industry, Håkan has also worked at Vifor Pharma Nordiska AB, Wyeth, SBL Vaccin AB and Astra.
”I am delighted to introduce Håkan Fröderberg as the new CEO of A+ Science AB,” says Mikael Nordenstjerna, Chairman of A+ Science. ”Håkan is an experienced leader with a broad network within the Nordic life science sector and it is inspiring to work together with Håkan and continue on developing A+ Science.”
Photo of Håkan Fröderberg: A+ Science
